CN101801973B - 6-三唑并哒嗪硫基苯并噻唑和苯并咪唑衍生物、其制备方法和作为药物和药物组合物的应用和作为met抑制剂的用途 - Google Patents
6-三唑并哒嗪硫基苯并噻唑和苯并咪唑衍生物、其制备方法和作为药物和药物组合物的应用和作为met抑制剂的用途 Download PDFInfo
- Publication number
- CN101801973B CN101801973B CN200880106250.6A CN200880106250A CN101801973B CN 101801973 B CN101801973 B CN 101801973B CN 200880106250 A CN200880106250 A CN 200880106250A CN 101801973 B CN101801973 B CN 101801973B
- Authority
- CN
- China
- Prior art keywords
- pyridazine
- benzothiazole
- triazolos
- sulfenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- FTJGPRQJWDVWHG-UHFFFAOYSA-N CCOC(CCC1)CC1=C Chemical compound CCOC(CCC1)CC1=C FTJGPRQJWDVWHG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR07/05789 | 2007-08-09 | ||
| FR0705789A FR2919870B1 (fr) | 2007-08-09 | 2007-08-09 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet |
| FR08/01819 | 2008-04-02 | ||
| FR0801819A FR2929613B1 (fr) | 2008-04-02 | 2008-04-02 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met |
| PCT/FR2008/001172 WO2009056692A2 (fr) | 2007-08-09 | 2008-08-06 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101801973A CN101801973A (zh) | 2010-08-11 |
| CN101801973B true CN101801973B (zh) | 2014-03-12 |
Family
ID=40524792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880106250.6A Expired - Fee Related CN101801973B (zh) | 2007-08-09 | 2008-08-06 | 6-三唑并哒嗪硫基苯并噻唑和苯并咪唑衍生物、其制备方法和作为药物和药物组合物的应用和作为met抑制剂的用途 |
Country Status (41)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| FR2945806B1 (fr) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met |
| FR2941229B1 (fr) * | 2009-01-21 | 2012-11-30 | Sanofi Aventis | Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| AU2009272517A1 (en) * | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as MET inhibitors |
| WO2010007316A2 (fr) * | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| FR2941949B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941950B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941951B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941952B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| EP2396333B1 (en) * | 2009-02-10 | 2013-07-03 | AstraZeneca AB | Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer |
| UY32623A (es) * | 2009-05-11 | 2010-12-31 | Astrazeneca Ab | Derivados bicíclicos para afecciones asociadas al receptor de andrógenos |
| MX336996B (es) | 2009-12-31 | 2016-02-09 | Hutchison Medipharma Ltd | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso. |
| FR2958292A1 (fr) * | 2010-03-30 | 2011-10-07 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| TW201202242A (en) | 2010-03-30 | 2012-01-16 | Sanofi Aventis | 6-(alkyl-or cycloalkyl-triazolopyridazine-sulfanyl)benzo-thiazole derivatives: preparation, and use as medicaments and as MET inhibitors |
| FR2966151B1 (fr) * | 2010-10-14 | 2012-11-09 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| AR085183A1 (es) | 2010-07-30 | 2013-09-18 | Lilly Co Eli | Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| JP5957526B2 (ja) | 2011-09-15 | 2016-07-27 | ノバルティス アーゲー | チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン |
| EP2872119A1 (en) * | 2012-07-12 | 2015-05-20 | Sanofi | Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea |
| WO2014076162A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| TWI695837B (zh) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| WO2016091891A1 (en) | 2014-12-09 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| US10047071B1 (en) | 2018-01-15 | 2018-08-14 | King Saud University | Dihydropyrimidinone derivatives |
| CN110317216A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑并哒嗪类衍生物在医药领域的应用 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN110041311B (zh) * | 2019-05-20 | 2021-03-19 | 东南大学 | 一种荧光探针分子ml-fp及其制备方法和应用 |
| WO2020251911A1 (en) * | 2019-06-12 | 2020-12-17 | Bristol-Myers Squibb Company | Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| WO2007075567A1 (en) * | 2005-12-21 | 2007-07-05 | Janssen Pharmaceutica, N.V. | Triazolopyridazines as tyrosine kinase modulators |
| WO2007138472A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| WO2008008539A2 (en) * | 2006-07-14 | 2008-01-17 | Amgen Inc. | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
| WO2008051808A2 (en) * | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2499995A1 (fr) | 1981-02-13 | 1982-08-20 | Roussel Uclaf | Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus. |
| US6528510B1 (en) * | 1998-09-11 | 2003-03-04 | Warner-Lambert Company | HIV protease inhibitors |
| EP1298125A1 (en) | 2001-09-26 | 2003-04-02 | Aventis Pharma S.A. | Substituted benzimidazole compounds and their use for the treatment of cancer |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
-
2008
- 2008-08-05 PA PA8792501A patent/PA8792501A1/es unknown
- 2008-08-06 SI SI200831106T patent/SI2178881T1/sl unknown
- 2008-08-06 PL PL08845285T patent/PL2178881T3/pl unknown
- 2008-08-06 MY MYPI2010000582A patent/MY152535A/en unknown
- 2008-08-06 MX MX2014000226A patent/MX340060B/es unknown
- 2008-08-06 CN CN200880106250.6A patent/CN101801973B/zh not_active Expired - Fee Related
- 2008-08-06 SG SG2012055091A patent/SG183077A1/en unknown
- 2008-08-06 DK DK08845285T patent/DK2178881T3/da active
- 2008-08-06 HR HRP20131182AT patent/HRP20131182T1/hr unknown
- 2008-08-06 RS RSP20130542 patent/RS53078B/sr unknown
- 2008-08-06 KR KR1020107005087A patent/KR101654376B1/ko not_active Expired - Fee Related
- 2008-08-06 JP JP2010519489A patent/JP5694767B2/ja not_active Expired - Fee Related
- 2008-08-06 AU AU2008320791A patent/AU2008320791B2/en not_active Ceased
- 2008-08-06 BR BRPI0815606 patent/BRPI0815606A2/pt active Search and Examination
- 2008-08-06 MX MX2010001593A patent/MX2010001593A/es active IP Right Grant
- 2008-08-06 PT PT08845285T patent/PT2178881E/pt unknown
- 2008-08-06 CA CA2884102A patent/CA2884102A1/fr not_active Abandoned
- 2008-08-06 EA EA201070235A patent/EA023465B1/ru not_active IP Right Cessation
- 2008-08-06 ES ES08845285T patent/ES2436657T3/es active Active
- 2008-08-06 EP EP08845285.9A patent/EP2178881B1/fr active Active
- 2008-08-06 NZ NZ583177A patent/NZ583177A/en not_active IP Right Cessation
- 2008-08-06 UA UAA201002523A patent/UA101328C2/uk unknown
- 2008-08-06 CA CA2695628A patent/CA2695628C/fr not_active Expired - Fee Related
- 2008-08-06 WO PCT/FR2008/001172 patent/WO2009056692A2/fr not_active Ceased
- 2008-08-06 ME MEP-2010-7A patent/ME00972B/me unknown
- 2008-08-07 PE PE2008001322A patent/PE20090900A1/es not_active Application Discontinuation
- 2008-08-07 AR ARP080103452 patent/AR068055A1/es unknown
- 2008-08-07 TW TW97130120A patent/TWI429649B/zh not_active IP Right Cessation
- 2008-08-07 JO JO2008361A patent/JO2935B1/en active
- 2008-08-08 UY UY31277A patent/UY31277A1/es not_active Application Discontinuation
- 2008-08-08 CL CL2008002351A patent/CL2008002351A1/es unknown
-
2010
- 2010-01-13 TN TNP2010000026A patent/TN2010000026A1/fr unknown
- 2010-01-26 US US12/693,736 patent/US8546393B2/en not_active Expired - Fee Related
- 2010-01-28 GT GT201000023A patent/GT201000023A/es unknown
- 2010-01-28 DO DO2010000040A patent/DOP2010000040A/es unknown
- 2010-01-29 CO CO10009506A patent/CO6251270A2/es active IP Right Grant
- 2010-02-03 CR CR11252A patent/CR11252A/es unknown
- 2010-02-03 NI NI201000022A patent/NI201000022A/es unknown
- 2010-02-04 IL IL20373410A patent/IL203734A/en not_active IP Right Cessation
- 2010-02-08 EC ECSP109944 patent/ECSP109944A/es unknown
- 2010-02-08 ZA ZA2010/00912A patent/ZA201000912B/en unknown
- 2010-03-01 MA MA32659A patent/MA31685B1/fr unknown
-
2013
- 2013-08-27 US US14/011,110 patent/US9115134B2/en not_active Expired - Fee Related
- 2013-12-13 CY CY20131101130T patent/CY1114906T1/el unknown
-
2015
- 2015-06-04 US US14/731,246 patent/US9321777B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| WO2007075567A1 (en) * | 2005-12-21 | 2007-07-05 | Janssen Pharmaceutica, N.V. | Triazolopyridazines as tyrosine kinase modulators |
| WO2007138472A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| WO2008008539A2 (en) * | 2006-07-14 | 2008-01-17 | Amgen Inc. | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
| WO2008051808A2 (en) * | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
Non-Patent Citations (1)
| Title |
|---|
| 6-Benzothiazolethiol, 2-amino-.RN 63493-81-2.《STN Registry数据库》.1984,索引信息. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101801973B (zh) | 6-三唑并哒嗪硫基苯并噻唑和苯并咪唑衍生物、其制备方法和作为药物和药物组合物的应用和作为met抑制剂的用途 | |
| AU2010271270B2 (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | |
| CN102378759A (zh) | 6-(6-o-取代的三唑并哒嗪-硫基)-苯并噻唑和苯并咪唑的衍生物、其制备方法、其作为药物的用途以及作为met抑制剂的用途 | |
| CN102159559A (zh) | 新型咪唑并[1,2-a]吡啶衍生物、其制备方法、其作为药物的用途、其药物组合物和新型用途特别是作为MET抑制剂的新型用途 | |
| CN102159543A (zh) | 新颖的三唑并[4,3-a]吡啶衍生物，其制备方法，其作为药物的用途，药物组合物及新颖的尤其是作为MET抑制剂的用途 | |
| CN104837844B (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| KR20110043680A (ko) | 이미다조[1,2-ａ]피리미딘 유도체, 그의 제조 방법, 의약으로서의 그의 용도, 제약 조성물, 및 특히 ｍｅｔ 억제제로서의 그의 용도 | |
| CN102369191A (zh) | 6-(6-取代的三唑并哒嗪-硫基)-5-氟苯并噻唑和5-氟苯并咪唑的衍生物、其制备方法、其作为药物的用途以及作为met抑制剂的用途 | |
| JP2012517409A (ja) | ６−（６−ｎｈ−置換−トリアゾロピリダジン−スルファニル）ベンゾチアゾールおよびベンゾイミダゾールの誘導体、これらの調製、これらの薬としての使用、ならびにこれらのｍｅｔ阻害剤としての使用 | |
| CN101273019A (zh) | 新的苯并咪唑和苯并噻唑衍生物，它们的制备方法，作为药物的应用，药物组合物和特别地作为C－Met抑制剂的新用途 | |
| CN102388029A (zh) | 6-(6-o-环烷基-或6-nh-环烷基-三唑并哒嗪-硫基)苯并噻唑和苯并咪唑的衍生物、其制备方法、其作为药物的用途以及其作为met抑制剂的用途 | |
| HK1145084B (en) | 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and use as met inhibitors | |
| HK1145084A (en) | 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and use as met inhibitors | |
| FR2929613A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met | |
| HK1156622A (en) | Imidazo [1,2-a] pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors | |
| HK1156612A (en) | Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1145084 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1145084 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140312 Termination date: 20170806 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |